Financhill
Sell
37

NNVC Quote, Financials, Valuation and Earnings

Last price:
$1.40
Seasonality move :
-9.51%
Day range:
$1.37 - $1.40
52-week range:
$0.94 - $2.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.54x
Volume:
124.7K
Avg. volume:
215.8K
1-year change:
-22.5%
Market cap:
$22.4M
Revenue:
--
EPS (TTM):
-$0.70

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
ATNM
Actinium Pharmaceuticals
-- -$0.35 -100% -7.24% $5.00
MTNB
Matinas BioPharma Holdings
-- -$0.78 -100% -45.83% --
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NNVC
Nanoviricides
$1.40 -- $22.4M -- $0.00 0% --
ATNM
Actinium Pharmaceuticals
$1.52 $5.00 $47.4M -- $0.00 0% --
MTNB
Matinas BioPharma Holdings
$1.03 -- $5.2M -- $0.00 0% 1.21x
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NNVC
Nanoviricides
-- -0.318 -- --
ATNM
Actinium Pharmaceuticals
-- -3.037 -- 9.03x
MTNB
Matinas BioPharma Holdings
-- 3.468 -- --
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
MTNB
Matinas BioPharma Holdings
-- -$1.9M -- -- -- -$2M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Nanoviricides vs. Competitors

  • Which has Higher Returns NNVC or ATNM?

    Actinium Pharmaceuticals has a net margin of -- compared to Nanoviricides's net margin of -11511.11%. Nanoviricides's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About NNVC or ATNM?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 365.95%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 228.95%. Given that Nanoviricides has higher upside potential than Actinium Pharmaceuticals, analysts believe Nanoviricides is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is NNVC or ATNM More Risky?

    Nanoviricides has a beta of 0.882, which suggesting that the stock is 11.802% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.

  • Which is a Better Dividend Stock NNVC or ATNM?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or ATNM?

    Nanoviricides quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Nanoviricides's net income of -$2.2M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Nanoviricides's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns NNVC or MTNB?

    Matinas BioPharma Holdings has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Matinas BioPharma Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    MTNB
    Matinas BioPharma Holdings
    -- -$0.33 --
  • What do Analysts Say About NNVC or MTNB?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 365.95%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 2812.62%. Given that Matinas BioPharma Holdings has higher upside potential than Nanoviricides, analysts believe Matinas BioPharma Holdings is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    MTNB
    Matinas BioPharma Holdings
    0 2 0
  • Is NNVC or MTNB More Risky?

    Nanoviricides has a beta of 0.882, which suggesting that the stock is 11.802% less volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.310, suggesting its more volatile than the S&P 500 by 30.998%.

  • Which is a Better Dividend Stock NNVC or MTNB?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or MTNB?

    Nanoviricides quarterly revenues are --, which are smaller than Matinas BioPharma Holdings quarterly revenues of --. Nanoviricides's net income of -$2.2M is lower than Matinas BioPharma Holdings's net income of -$1.7M. Notably, Nanoviricides's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 1.21x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
    MTNB
    Matinas BioPharma Holdings
    1.21x -- -- -$1.7M
  • Which has Higher Returns NNVC or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Nanoviricides's net margin of -49.65%. Nanoviricides's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About NNVC or NBY?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 365.95%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Nanoviricides has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nanoviricides is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is NNVC or NBY More Risky?

    Nanoviricides has a beta of 0.882, which suggesting that the stock is 11.802% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock NNVC or NBY?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or NBY?

    Nanoviricides quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Nanoviricides's net income of -$2.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Nanoviricides's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns NNVC or OGEN?

    Oragenics has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About NNVC or OGEN?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 365.95%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Nanoviricides, analysts believe Oragenics is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    OGEN
    Oragenics
    0 1 0
  • Is NNVC or OGEN More Risky?

    Nanoviricides has a beta of 0.882, which suggesting that the stock is 11.802% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock NNVC or OGEN?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or OGEN?

    Nanoviricides quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Nanoviricides's net income of -$2.2M is higher than Oragenics's net income of -$2.2M. Notably, Nanoviricides's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns NNVC or TOVX?

    Theriva Biologics has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About NNVC or TOVX?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 365.95%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Nanoviricides, analysts believe Theriva Biologics is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is NNVC or TOVX More Risky?

    Nanoviricides has a beta of 0.882, which suggesting that the stock is 11.802% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock NNVC or TOVX?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or TOVX?

    Nanoviricides quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Nanoviricides's net income of -$2.2M is higher than Theriva Biologics's net income of -$4.3M. Notably, Nanoviricides's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock